A5033584583- Acute Myeloid Leukemia Research
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Multiple Sclerosis Research Studies
- Inertial Sensor and Navigation
- Autoimmune Neurological Disorders and Treatments
- Acute Lymphoblastic Leukemia research
- Peripheral Neuropathies and Disorders
- Epilepsy research and treatment
- Space Satellite Systems and Control
- GNSS positioning and interference
- Distributed Control Multi-Agent Systems
- Neuroinflammation and Neurodegeneration Mechanisms
- Systemic Lupus Erythematosus Research
- Neuroscience and Neuropharmacology Research
- Hereditary Neurological Disorders
- Neurogenesis and neuroplasticity mechanisms
- Neonatal and fetal brain pathology
- Spine and Intervertebral Disc Pathology
- Underwater Vehicles and Communication Systems
- Spacecraft Dynamics and Control
- CNS Lymphoma Diagnosis and Treatment
- Pharmacological Effects and Toxicity Studies
- Neonatal Respiratory Health Research
- Cancer-related gene regulation
Renji Hospital
2016-2025
Shanghai Jiao Tong University
2017-2024
Astex Pharmaceuticals
2015-2024
University of Lübeck
2024
University Medical Center of the Johannes Gutenberg University Mainz
2024
Johannes Gutenberg University Mainz
2024
Harbin Engineering University
2013-2023
Army Medical University
2018
National Natural Science Foundation of China
2017
Second Military Medical University
2011-2014
To characterize the genomic landscape and leukemogenic pathways of older, newly diagnosed, non-intensively treated patients with AML to study clinical implications, comprehensive genetics analyses were performed including targeted DNA sequencing 263 genes in 604 a prospective Phase III trial. Leukemic trajectories delineated using oncogenetic tree modeling hierarchical clustering, prognostic groups derived from multivariable Cox regression models. Clonal hematopoiesis-related (ASXL1, TET2,...
Timely screening of neuromyelitis optica spectrum disorder (NMOSD) and differential diagnosis from myelin oligodendrocyte glycoprotein associated (MOGAD) are the keys to improving quality life patients. Metabolic disturbance occurs with development NMOSD. Still, advanced tools required probe metabolic phenotype Here, we developed a fast nanoparticle-enhanced laser desorption/ionization mass spectrometry assay for multiplexing fingerprints (MFs) trace plasma cerebrospinal fluid (CSF) samples...
Abstract Purpose: Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing cancer. This randomized phase II trial compared guadecitabine, a second-generation HMA, and (G+C) against second-line chemotherapy women measurable or detectable platinum-resistant Patients Methods: received either G+C (guadecitabine 30 mg/m2 s.c. once-daily for 5 days carboplatin) treatment of choice (TC; topotecan,...
Abstract Aims Activated microglia have been found in the forebrains and hippocampi of temporal lobe epilepsy (TLE) patients status epileptic (SE) animal models. The peroxisome proliferator‐activated receptor γ (PPAR γ) agonist rosiglitazone has shown to prevent microglial activation. However, its role pilocarpine‐induced epilepticus remains unknown. We aimed examine effect PPAR protecting against resulting from over‐activation explore phenotypic changes as underlying mechanism. Methods Male...
BACKGROUND Outcomes for patients with relapsed or refractory acute myeloid leukemia (AML) are poor. Guadecitabine, a next‐generation hypomethylating agent, could be useful in treating such patients. METHODS In this multicenter, open‐label, phase 2 dose‐expansion study, AML from 10 North American medical centers were first randomized (1:1) to receive subcutaneous guadecitabine at 60 90 mg/m on 5 consecutive days each 28‐day cycle (5‐day regimen). Subsequently, another cohort was treated...
Early identification of patients with bipolar disorder during their first depressive episode is beneficial to the outcome and treatment, but traditionally this has been a great challenge clinicians. Recently, brain-derived neurotrophic factor (BDNF) suggested be involved in pathophysiology major (MDD), it not clear whether BDNF levels can used predict among episode.To explore differentiate between MDD episode.A total 203 as well 167 healthy controls were recruited. After 3 years bi-annual...
Abstract Introduction Neuromyelitis optica spectrum disorders (NMOSD), mainly mediated by B cells and AQP4 antibody, has a high rate of recurrence. Telitacicept is novel drug specifically targeting the upstream signaling for activation cell with its following production autoimmune antibodies. Thus, it may be promising approach. Our study preliminarily explored potential safety effectiveness plasma exchange in treatment recurrent NMOSD. Methods This was single‐center, single‐arm, open‐label...
Guadecitabine is a novel hypomethylating agent (HMA) resistant to deamination by cytidine deaminase. Patients with relapsed/refractory acute myeloid leukemia (AML) were randomly assigned guadecitabine or preselected treatment choice (TC) of high-intensity chemotherapy, low-intensity HMAs low-dose cytarabine, best supportive care (BSC). The primary end point was overall survival (OS). A total 302 patients (n = 148) TC 154). Preselected TCs 233 [77%; mainly HMAs]), chemotherapy 63 [21%]), and...
Objectives. To analyze, in extremely low birth weight infants, associations between peak bilirubin concentration and evidence of brain damage, blindness attributable to retinopathy prematurity. Methods. Retrospective study 128 infants ≤800 g ≤27 weeks gestation born 1980 1989 discharged from a tertiary neonatal intensive care unit. After screening analyses, multivariable analyses were conducted identify (dichotomized at different levels create 3 binary variables), severe adverse...
This phase 3 study evaluated the efficacy and safety of new hypomethylating agent guadecitabine (n = 408) vs a preselected treatment choice (TC; n 407) azacitidine, decitabine, or low-dose cytarabine in patients with acute myeloid leukemia unfit to receive intensive induction chemotherapy. Half (50%) had poor Eastern Cooperative Oncology Group Performance Status (2-3). The coprimary end points were complete remission (19% 17% for TC, respectively [stratified P .48]) overall survival (median...